$-0.47
(Market cap
$2,409 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
39.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.2
-
Face value
--
-
Shares outstanding
62,849,457
8 Years Aggregate
CFO
$-728.22 Mln
EBITDA
$-1,106.09 Mln
Net Profit
$-1,127.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| 38.2 | -7.8 | 10.1 | 313.8 | 157.3 | -16.9 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| 181.0 | 224.2 | -57.5 | -91.6 | -42.3 | 104.2 | 913.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
|
38.7 | 2,409.0 | 0.0 | -242.0 | -- | -221.5 | -- | 39.4 |
| 85.4 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 248.4 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 73.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.5 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 537.3 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.8 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 351.6 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.8 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Kodiak Sciences (KOD)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular... endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Read more
-
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
-
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
-
Headquarters
Palo Alto, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kodiak Sciences (KOD)
What is the current share price of Kodiak Sciences Inc (KOD) Today?
The share price of Kodiak Sciences Inc (KOD) is $38.65 (NASDAQ) as of 28-Aug-2026 10:37 EDT. Kodiak Sciences Inc (KOD) has given a return of 157.26% in the last 3 years.
What is the current PB & PE ratio of Kodiak Sciences Inc (KOD)?
Since, TTM earnings of Kodiak Sciences Inc (KOD) is negative, P/E ratio is not available.
The P/B ratio of Kodiak Sciences Inc (KOD) is 39.39 times as on 21-Aug-2026, a 636 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.47 |
9.45 |
2024 |
-2.97 |
3.49 |
2023 |
-0.61 |
0.60 |
2022 |
-1.12 |
0.86 |
2021 |
-16.51 |
6.64 |
What is the 52 Week High and Low of Kodiak Sciences Inc (KOD)?
The 52-week high and low of Kodiak Sciences Inc (KOD) are Rs 47.84 and Rs 8.29 as of 28-Aug-2026.
What is the market cap of Kodiak Sciences Inc (KOD)?
Kodiak Sciences Inc (KOD) has a market capitalisation of $ 2,409 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kodiak Sciences Inc (KOD)?
Before investing in Kodiak Sciences Inc (KOD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.